



Marksans Pharma Ltd.

Date: June 01, 2026

BSE Limited

Corporate Relation Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001.

Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.

Symbol: MARKSANS

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015– Acquisition of QliniQ B V.

Dear Sirs/Madam,

Kindly find enclosed herewith a Press Release dated June 01, 2026 titled “**Marksans Pharma to Acquire 100% of Netherlands-based QliniQ B.V., Strengthening Presence in European Markets**”.

Enclosed herewith also find details required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/ 4/2015 dated September 9, 2015 given in **Annexure A** to this letter.

For Marksans Pharma Limited

Harshavardhan Panigrahi
Company Secretary

Enclosed as above

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W),
Mumbai - 400 053 Tel.: +91 22 4001 2000

E-mail: companysecretary@marksanspharma.com

www.marksanspharma.com



Marksans Pharma Ltd.

Marksans Pharma to Acquire 100% of Netherlands-based QliniQ B.V., Strengthening Presence in European Markets

Mumbai, June 1, 2026 – Marksans Pharma Ltd (NSE: MARKSANS | BSE: 524404), one of India's fastest-growing pharmaceutical companies, today announced that it has entered into a definitive agreement to acquire 100% of the share capital of QliniQ B.V., a profitable Netherlands-based pharmaceutical company with established front-end sales, marketing, and distribution capabilities across the Dutch healthcare market.

The acquisition marks a strategic step in expanding Marksans' presence across regulated European markets and strengthening its forward-integration strategy through direct, owned market-access capabilities in the European Union.

QliniQ operates a differentiated portfolio of niche pharmaceuticals and medical devices, with established positions across women's health, dermatology, respiratory care, and other specialty categories. The company has developed long-standing relationships across wholesalers, pharmacies, hospitals and insurer-led tender channels in the Netherlands, supporting sustainable market access and growth. For the financial year ended 31 December 2025, QliniQ reported revenue of €9.35 million and net profit of €1.01 million. The company has delivered strong profitable growth, with revenue increasing at a CAGR of approximately 41% between FY2023 and FY2025, while maintaining a debt-free balance sheet.

Commenting this acquisition, Albert de Bruin and Raymond Lansink, Board members and Shareholders of QliniQ B.V. said, *"We are delighted that QliniQ is becoming part of the Marksans Group. During our discussions with Marksans, we were particularly impressed by the Company's strong track record in product development, its clear long-term vision, and its commitment to quality and innovation. Marksans has built strong product development capabilities, a broad and growing portfolio, and high-quality manufacturing expertise. Combining these strengths with QliniQ's market presence and local expertise creates a compelling opportunity for future growth and value creation. Most importantly, we share a common ambition: to improve access to high-quality medicines and create long-term value for patients, healthcare providers, business partners, and employees. We are excited about the opportunities ahead and look forward to working closely with the Marksans team to build on our shared growth ambitions."*

Commenting on the acquisition, Mark Saldanha, Chairman and Managing Director of Marksans Pharma, said, *"This acquisition represents an important strategic step in expanding Marksans' presence across regulated European markets. QliniQ has built a profitable niche portfolio supported by established market access capabilities, long-standing customer relationships, and tender participation across the Netherlands healthcare ecosystem. The acquisition provides Marksans with direct access to the Netherlands market and enhances our ability to commercialize existing and future products across regulated European markets. We believe this acquisition will strengthen our long-term growth opportunities and further enhance our global business."*

The acquisition provides Marksans with:

- Established sales, marketing and distribution capabilities in the Netherlands, one of Europe's key pharmaceutical markets.
- Access to long-standing relationships with leading wholesalers, pharmacies, hospitals and health insurers.

- Participation in insurer-led tender channels with visibility across multiple products and established relationships with leading Dutch health insurers.
- EU GDP-compliant warehousing, wholesale distribution and regulatory infrastructure.
- Multiple routes to market through wholesalers, pharmacies and direct-to-consumer channels.
- Enhanced market access capabilities to support future portfolio expansion across Europe.

The acquisition is expected to support commercialization of Marksans’ existing and future product portfolio in the Netherlands and strengthen its long-term presence across regulated European markets.

About QliniQ B.V:

QliniQ B.V. is a privately owned, Netherlands-based pharmaceutical and medical-products company engaged in the distribution and commercialization of niche prescription medicines and medical devices. Headquartered in Oldenzaal, it operates across wholesaler, pharmacy, hospital and insurance-led tender channels in the Netherlands, supported by its own EU GDP-licensed wholesale and warehousing capability and a direct-to-customer webshop. Its portfolio spans women’s health (contraceptives and menopause), dermatology, respiratory/ENT, endocrinology and gastroenterology, with several first-to-market positions and limited direct competition. QliniQ has established participation across insurer-led tender channels, supporting market access across multiple product categories.

The company has delivered strong, profitable growth, with audited net turnover rising to €9.35 million in FY2025 (year ended 31 December) — a revenue CAGR of approximately 41% from FY2023 — while remaining consistently profitable.

Key audited financials (€; FY ended 31 December)

Particulars (€)	FY2025
Net turnover	9,346,227
Profit before tax	1,337,388
Net profit	1,007,652
Equity (net worth, 31 Dec)	1,452,862

About Marksans Pharma Ltd

Marksans Pharma Limited (BSE: 524404 | NSE: MARKSANS) (www.marksanspharma.com) is a Mumbai-headquartered global pharmaceutical company engaged in the research, manufacturing, marketing and sale of pharmaceutical formulations. Incorporated in 1992 and led by founder Chairman & Managing Director Mr. Mark Saldanha, the Company markets a broad portfolio of generics and OTC products across multiple international markets, with its principal regions being the United States and North America, the United Kingdom and Europe, and Australia and New Zealand. Marksans operates regulatory-approved manufacturing facilities. For the financial year ended 31 March 2026, Marksans reported consolidated total income of approximately ₹3,033 crore and profit after tax of approximately ₹420 crore. Global healthcare investor OrbiMed has been a strategic shareholder since 2021.

Disclaimer

Certain statements in this press release may contain forward-looking statements, including, but not limited to, statements regarding the Company’s business strategies, operations, financial condition, and future performance. These forward-looking statements are based on current expectations, assumptions, and estimates, and are subject to known and unknown risks, uncertainties, and other factors that may cause

actual results, performance, or achievements to differ materially from those expressed or implied. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

Contact Information

Jitendra Sharma, CFO

Marksans Pharma Ltd

Tel: +91 22 40012000

jitendra@marksanspharma.com

Registered Office

11th Floor, "Grandeur"

Off Veera Desai Extension Road

Oshiwara, Andheri West

Mumbai, Maharashtra, 400 053

Telephone: +91 224001 2000

Fax: +91 224001 2011

CIN: L24110MH1992PLC066364

ISIN: INE750C01026

NSE Code: MARKSANS

BSE CODE: 524404

Website: <http://www.marksanspharma.com>



Marksans Pharma Ltd.

Annexure A

Disclosure under Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sr. No.	Details of Events that need to be provided	Information of such events(s)
1	Name of the target entity, details in brief such as size, turnover etc.	QliniQ B.V. is a foreign company registered in the Netherlands engaged in the business of distribution of medical devices and pharmaceutical products in the Netherlands with an annual turnover of € 9,346,227 and net-worth of € 1,452,862 as on December 31, 2025.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	The transaction is between the Company and the shareholders of QliniQ B.V., who are not related party to the Company. As such, the transaction will not fall within related party transaction(s) for the Company. Further, promoter/promoter group of the Company have no interest in QliniQ B. V.
3	Industry to which the entity being acquired belongs	QliniQ B.V. is engaged in the business of distribution of medical devices and pharmaceutical products in the Netherlands.
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	This acquisition will enable Marksans to use the front-end sales and marketing infrastructure of QliniQ B.V. for marketing its products manufactured in India, UK, and USA regions. It will bolster Marksans' presence in the European markets.
5	Brief details of any governmental or regulatory approvals required for the acquisition	No approval will be required for the acquisition.
6	Indicative time period for completion of the acquisition	The acquisition is expected to be completed by 15 June 2026 or any other date as the Parties agree in writing.
7	Nature of consideration -whether cash consideration or share swap and details of the same	Cash consideration
8	Cost of acquisition or the price at which the shares are acquired	The Company will acquire entire shareholding of QliniQ B.V. for a total consideration of € 7,500,000
9	Percentage of shareholding / control acquired and / or number of shares acquired	The Company will acquire 100% share capital of QliniQ B.V.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	QliniQ B.V. is engaged in the purchase and sale of, promotion of pharmaceutical products as well as medical devices. It operates across wholesaler, pharmacy, hospital and insurance-led tender channels in the Netherlands, supported by its own EU GDP-licensed wholesale and warehousing capability and a direct-to-customer webshop. For the year ended 31 December 2025, QliniQ B.V. posted turnover of Euro 9,346,227 (INR 985 Mn) and net income of Euro 1,007,652 (INR 106 Mn). The company has Zero debt in its books.

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W),
Mumbai - 400 053 Tel.: +91 22 4001 2000

E-mail: companysecretary@marksanspharma.com

www.marksanspharma.com